PRODIGE23

PRODIGE23, long term results now published

Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared a paper by Thierry Conroy et al. on X:

“PRODIGE23.

Long term results now published!

T3-4 rectal adenocarcinoma Randomized:

CRT to FOLFOX mFOLFIRINOX to CRT to FOLFOX

Improved OS!!!

Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS.”

PRODIGE23

Source: Krishan Jethwa/X

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Authors: T. Conroy, F. Castan, P.-L. Etienne, E. Rio, N. Mesgouez-Nebout, L. Evesque, V. Vendrely, X. Artignan, O. Bouché, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardière, A. Boilève, M. Delaye, S. Gourgou, V. Pezzella, and C. Borg.

PRODIGE23

A. Boilève C. Borg C. de la Fouchardière C. Louvet C. Morand cancer D. Gargot E. Rio F. Castan FOLFIRINOX FOLFOX JANUS Krishan Jethwa L. Evesque M. Delaye N. Bonichon-Lamichhane N. Mesgouez-Nebout O. Bouché OncoDaily Oncology P.-L. Etienne PRODIGE23 rectal adenocarcinoma S. Gourgou Thierry Conroy V. Boige V. Pezzella V. Vendrely X. Artignan